Current Clinical PhD students include:
Current Academic Clinical Lecturers include:
Dr. Rona Smith
The EMI scheme recognises individuals or projects who don’t have a home department and welcome them to be part of the EMI Community, provided that they meet the criteria of the EMI Scheme. This will usually involve an internal approval by the EMI Steering Committee. In this way, they will be open to engaging with expertise and advice from our panel of supervisors and industry partners, as well as attend trainings or events we hold.
Current EMI Community members include:
Dr. Omar Mukhtar
Current Clinical PhD students
Constanza is a Medical Oncologist. She qualified in Argentina and did her oncology training at Vall D’Hebron University Hospital in Barcelona. In January 2016 Constanza started working at Addenbrooke’s Early Phase Unit. During this period, she developed a clinical trial where patients with solid tumours were going to receive durvalumab (PD-L1 inhibitor). In October 2016 joined the Fitzgerald’s lab as a PhD student. Her research project will be focused on understanding EAC from a multidimensional perspective. Using samples from patients with EAC she will characterize their immune landscape, and correlate this with their genetic signatures and clinical data.
Jamie is a clinical radiologist interested in a variety of musculoskeletal conditions, particularly osteoarthritis (OA). His research to date has focused on assessment of subchondral bone and osteochondral junction in knee OA using novel magnetic resonance (MR) imaging acquisition and analysis techniques. His PhD research will focus on the development of novel MR techniques for use in experimental medicine studies of OA.
Audrey graduated with a medical degree from University College Dublin. She completed her medical subspecialty training in Endocrinology and Diabetes with the Royal College of Physicians Ireland. Audrey is undertaking a PhD within the Department of Clinical Biochemistry supported by the Experimental Medicine Training Initiative. Her research will focus on the influence of genetic variation in PPARA on lipid metabolism in humans.
Petra graduated as a Medical doctor from the University of Zagreb in 2005, and completed her clinical training in Internal Medicine. She worked as a Consultant in Internal medicine, with significant involvement with the Diabetes and Endocrinology division, where she was also exposed to wide spectrum of teaching roles of undergraduates, junior doctors and GPs. She continued this theme on joining the Department of Endocrinology and Diabetes at Cambridge University Hospitals as a Clinical Fellow. She is currently a fully funded EMI/Astra Zeneca/MedImmune PhD student, undertaking research in experimental medicine studies, which will be carried out in volunteers and patients with diabetes. Her research will focus on understanding the role of the peptide hormones apelin and relaxin in human physiology, and establishing their potential as novel agents for the treatment of diabetes and heart failure.
Zoe obtained a first class degree in Medical Sciences as an Intercalated BSc (Hons). Her research focused on the role of SIGN-R1, mouse homologue of the human DC-SIGN in the pathophysiology of visceral Leishmaniasis. She used micro-array technology to detect changes in gene expression in mouse spleen following Leishmania infection and confirmed a redundant role for this adhesion and immune-modulating receptor using a construct SIGN-R1 cell line. After completing her MB BS (Hons) Medicine, she obtained her MRCS (Eng) during Foundation Training. She was awarded the NIHR Academic Clinical Fellow in Vascular Surgery for Yorkshire and Humber where she carried out a series of clinical research studies before entering higher surgical training in Vascular Surgery. She has been appointed as an EMI / GSK funded doctoral research training fellow and her work will focus on the cardiovascular effects of erythropoiesis stimulating agents (ESAs).
Arlette graduated as a Doctor of Medicine and Surgery from the Malta Medical School, University of Malta. She undertook her basic clinical training in acute care in Malta and Dundee, before taking up an NIHR Academic Clinical Fellowship in Intensive Care Medicine at St George’s, University of London. The academic component of her training, undertaken at the University of Cambridge, focused on the functional phenotype of de-primed neutrophils. She is now an Experimental Medicine Training Initiative (EMI)-funded PhD student at the University of Cambridge, where she is investigating the role of differential TNF receptors on neutrophil effector functions.
Elizabeth graduated with an MBBS and BMedSci in Molecular Medicine from Barts and the London School of Medicine and Dentistry in London. She then undertook Academic Foundation Training, with a research post in Virology at the Royal Free Hospital where she studied the role of IL28B SNPs in response to HIV treatment. She continued her medical training as an NIHR funded Academic Clinical Fellow in Surgery at Addenbrooke’s Hospital, Cambridge, where she investigated the role of CD8 T cells in graft rejection. She is currently an EMI/ACT funded PhD student at the University of Cambridge, her research is focused on the role of inflammasome products in ischaemia-reperfusion injury in human kidneys.
Clinical PhD Student, Experimental Medicine and Immunotherapeutics/AstraZeneca
Takahiro started his Clinical PhD with EMIT and Translational Safety at AstraZeneca in January 2016. He is a Clinical Pharmacology and Therapeutics trainee and was based at Guy’s and St Thomas’ Hospitals with the Clinical Toxicology department prior to commencing his studentship. His research interests include the cardiovascular effects of drugs and the current research project aims to generate unique human cardiovascular haemodynamic data which will be used to build quantitative PKPD systems models of the human cardiovascular system in health and disease.
Current Academic Clinical Lecturers
Filipe Correia Martins is an Academic Clinical Lecturer in Gynaecological Oncology. He conducts his research on HGSOC, which is the most common and an agressive form of ovarian cancer, with reduced chemotherapy response in recurrent disease. Overall survival is virtually unchanged over the last two decades. It is a very heterogeneous disease and understanding its key drivers is crucial to stratify patients and develop effective personalised therapies. Filipe has recently found that an important gene called PTEN is suppressed in >50% of the cases and that this suppression is associated with shorter survival. His current project will validate a method to test drug response in the lab and use it to identify Astrazeneca drugs that target PTEN alterations and tumour features that predict response to these compounds. This work will impact ovarian cancer management and treatment because we will validate tumour markers for routine clinical stratification of patients and for robust clinical trials of new drugs that can potentially be used to treat the most aggressive forms of HGSOC.
Dr. Rona Smith
Current EMI Community members
Sanjeev is a Medical Oncologist who completed his training in Sydney, Australia. He moved to the UK in 2015 to work at Addenbrooke’s Hospital in the drug development unit. He is now undertaking a full-time PhD in Jason Carroll’s laboratory at the CRUK CI having been awarded a Cambridge Cancer Centre Clinical Research Fellowship, where he is the coordinating investigator for the PIONEER trial. This study translates the lab’s work into hormonal cross-talk between the nuclear receptors ERα and PR into patients with ER-positive breast cancer. In the lab, using ChIP-seq and RIME, he plans to delineate the molecular mechanisms of ERα-PR cross-talk in breast cancer model systems with known PR ligands, but also via the characterisation of other novel agents with in vivo and explant models. He is also exploring the role of progestins in the setting of ESR1 mutations in breast cancer.
Doreen is a Cancer Research UK Cambridge Centre and Cambridge Trust funded PhD scholar. She graduated with a Master of Research in Bioimaging Sciences (Distinction) at Imperial College London. Her postgraduate research at the Imperial College London Cancer Imaging Centre involved the preclinical imaging and pharmacology of various cancer hallmarks including apoptosis, metabolism and metastasis. Prior to her Master’s, Doreen had 4 years of working experience as a biologist at the Agency for Science, Technology and Research (A*STAR), and as a clinical researcher at the Singapore General Hospital Department of Radiology under the A*STAR Biomedical Engineering Programme Initiative. Her current PhD project involves the development of novel methods to image leukocyte infiltration into tumours as biomarkers of cancer immunotherapy in both patients and animal models. She is co-supervised by Dr. Ferdia Gallagher (Department of Radiology), Prof. Klaus Okkenhaug (Department of Pathology/The Babraham Institute), Prof. Edwin Chilvers (Department of Medicine) and Dr. Pippa Corrie (Department of Oncology), and is collaborating with the pharmaceutical industry for her PhD.
Laura is a chemist with special interest in radiopharmaceutical chemistry and Positron Emission Tomography (PET). She graduated with a Bachelor and Master of Science (Chemistry/Radiopharmaceutical Chemistry) from the Technical University of Munich (TUM). Her main postgraduate research was focused on the development of novel inhibitors for the prostate specific membrane antigen (PSMA). Laura spent most of that time at the Peter MacCallum Cancer Centre in Melbourne and the University of Melbourne where she preclinically evaluated two 64Cu-labelled PSMA inhibitors and also worked with 68Ga. She is currently doing a PhD in the department of Radiology that focuses on the development of 89Zr Immuno-PET for cellular imaging.
Dr. Omar Mukhtar
Martin obtained his medical degree (MD.CM) at McGill University and completed Medical Oncology residency at the British Columbia Cancer Agency in Vancouver, Canada. He is currently a PhD student in Duncan Jodrell’s pharmacology and drug development group at the Cancer Research UK Cambridge Institute. He is investigating the immunomodulatory effects of CXCR4 antagonism on the tumour microenvironment in pancreatic cancer. Pre-clinical studies have demonstrated synergy between CXCR4 antagonism and checkpoint inhibition with anti-PD-L1 in controlling pancreatic tumour growth. This observation is now being translated in a proof of concept experimental medicine study at Addenbrooke’s Hospital for patients with ovarian, colorectal, and pancreatic cancer.
Interventional Research Fellow at Papworth Hospital; Academic Clinical Fellow at Cambridge University Hospitals
Dr. Zhao studied medicine at Christ’s College, the University of Cambridge before completing his training in London. He was appointed an Academic Foundation Trainee in Cardiology at King’s College Hospital. Subsequently, Tian was appointment an Academic Clinic Fellow in Cardiology at Addenbrooke’s where he also completed his MPhil in Transitional Medicine and Therapeutics. Currently, Tian is a Cardiology Specialist Registrar and has taken time out to complete a Clinical PhD at Cambridge under the supervision of Professor Mallat, Dr. Cheriyan, Dr. Hoole and Dr. Rudd. His areas of interest are early stage clinical trials, immune-modulation in coronary heart disease and the coronary microcirculation.